CSI Market
Sign In | Register

Human Genome Sciences Inc (HGSI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access HGSI quarterly Cash Flow →
This cash flow overview for Human Genome Sciences Inc spans from to Dec 31 2009, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2009)
12 Months
Operating Activities
Income5.66
Depreciation & amortization41.22
Amortization of Other Assets21.94
Increase (Decrease) in Deferred Revenue17.23
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories20.15
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation13.11
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction38.87
Impairment Of Investments-
Business Exit Costs-
Increase Decrease In Collaboration Receivables-
Increase Decrease In Collaboration Payable-
Income taxes0.00
Losses/ -gains on Investments net5.26
Accounts Receivable33.94
Increase (Decrease) in Accounts Payable and Accrued Liabilities-9.15
Accrued Expense-1.95
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.64
Other Working Capital1.86
Other Noncash Income (Expense)-3.76
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.33
Investing Activities
Capital Expenditures-10.02
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities388.28
Payments to Acquire Marketable Securities-625.04
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)-20.58
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates5.26
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities3.29
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-238.23
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-50.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock456.39
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Purchase Of Capped To Call Options-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities790.98
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.35
Total Cash Flow552.42
4 historic quarters locked

Sign in to unlock the full Human Genome Sciences Inc cash flow history.

Sign In Create Free Account

About HGSI Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License